FDA Panel Backs Atezolizumab for mTNBC -- at Least for Now FDA Panel Backs Atezolizumab for mTNBC -- at Least for Now

FDA advisers voted 7-2 for keeping in place an approval for atezolizumab for a kind of metastatic triple-negative breast cancer while urging drugmaker Genentech to continue research on this indication.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news